Lung Cancer Clinical Trial

Use of Harmonic Scalpel to Decrease Lymphatic and Chest Tube Drainage After Lymph Node Dissection With Lobectomy.

Summary

In an effort to elucidate whether the Harmonic Scalpel will improve sealing lymphatics and decrease lymphatic drainage thereby decreasing the length of time that chest tubes are required and minimizing length of stay; the Harmonic Scalpel will be compared to a control group which uses electrocautery. This study will assess these two different methods to determine if there is a notable decrease in the amount of drainage with one versus the other.

View Full Description

Full Description

Lymph node dissection is an integral part of the surgical management of lung cancer. Knowledge of lymph node status plays a key role in therapeutic decision making and prognosis. Associated with this dissection comes the propensity for lymphatic leakage, increased chest tube drainage, prolonged retention of chest tubes in the postoperative period and increased patient length of stay. Our center performs complete mediastinal node dissection of all relevant regional lymph nodes which generally include paratracheal, pretracheal, subcarinal, hilar and paraesophageal nodes. The current standard of practice for the dissection of the lymph nodes includes the use of the Harmonic Scalpel or electrocautery. Known risk of electrocautery include localized nerve damage, cardiac arrhythmias and damage to the tissue sample/specimen that is used for pathology. The Harmonic Scalpel technology has recently become available for use. Current experience with the Harmonic Scalpel suggests that there is less localized nerve damage, less incidence of arrhythmias, less damage to the tissue sample and less lymph leakage. There is no published data to support this hypothesis, thus the purpose of this study.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Patients undergoing resection for stage 1, 2 or 3A lung cancer.
Patients between the ages of 20-75.

Exclusion Criteria:

History of Congestive Heart Failure.
History of renal failure, ie., creatinine greater than 2.2.
Patients with bulky or matted lymph nodes in stage 3A.
Current pregnancy.
Current participation in another study involving an investigational device or drug.

Study is for people with:

Lung Cancer

Estimated Enrollment:

50

Study ID:

NCT00591552

Recruitment Status:

Recruiting

Sponsor:

Sentara Cardiovascular Research Institute

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Sentara Norfolk General Hospital/Sentara Heart Hospital
Norfolk Virginia, 23507, United States More Info
Laura Pine, RN, BSN
Contact
757-388-2732
[email protected]
Michelle Collier, RN, BSN
Contact
757-388-7511
[email protected]
Kirk Fleischer, MD
Sub-Investigator
Michael McGrath, MD
Sub-Investigator
Jeffrey Rich, MD
Sub-Investigator

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Estimated Enrollment:

50

Study ID:

NCT00591552

Recruitment Status:

Recruiting

Sponsor:


Sentara Cardiovascular Research Institute

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider